Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA

Nanomedicine

Volumn 7, Issue 4, 2012, Pages 475-491

  Rodriguez, B Leticia ^a   Li, Xinran ^a   Kiguchi, Kaoru ^a   Digiovanni, John ^a   Unger, Evan C ^b   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

apoptosis; breast tumor; dsRNA therapy; epidermoid carcinoma; liposome; plasmid uptake

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED RNA REPLICASE BASED PLASMID DNA; LIPOPLEX; LIPOSOME; PLASMID DNA; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; TUMOR REGRESSION; ZETA POTENTIAL;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; DNA; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PLASMIDS; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA REPLICASE;

EID: 84859497406     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.112     Document Type: Article

References (44)

1. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36(12), 3371-3380 (2006). (Pubitemid 44932738)
2. Absher M, Stinebring WR. Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator. Nature 223(5207), 715-717 (1969).
3. Chawla-Sarkar M, Lindner DJ, Liu YF et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237-249 (2003). (Pubitemid 36749609)
4. Diebold SS, Schulz O, Alexopoulou L et al. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther. 16(3), 359-366 (2009).
5. Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028), 887-892 (2005). (Pubitemid 40314900)
6. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413(6857), 732-738 (2001). (Pubitemid 33009951)
7. Friedrich I, Shir A, Klein S, Levitzki A. RNA molecules as anti-cancer agents. Semin. Cancer Biol. 14(4), 223-230 (2004). (Pubitemid 38824583)
8. Hirabayashi K, Yano J, Inoue T et al. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 59(17), 4325-4333 (1999). (Pubitemid 29418751)
9. Okada C, Akbar SM, Horiike N, Onji M. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int. 25(3), 595-603 (2005). (Pubitemid 40861909)
10. Pimm MV, Baldwin RW. Treatment of transplanted rat tumours with double-stranded RNA(BRL 5907). II. Treatment of pleural and peritoneal growths. Br. J. Cancer 33(2), 166-171 (1976).
11. Le UM, Kaurin DG, Sloat BR, Yanasarn N, Cui Z. Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant antitumor activity. Radiother. Oncol. 90(2), 273-279 (2009).
12. Le UM, Yanasarn N, Lohr CV, Fischer KA, Cui Z. Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol. Ther. 7(3), 440-447 (2008). (Pubitemid 351847065)
13. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60(7), 805-812 (2008).
14. Meier H, Myers DD, Huebner RJ. Ineffectiveness of poly rI:rC on transplanted tumors induced by methylcholanthrene. Naturwissenschaften 57(5), 248-249 (1970).
15. Cui Z, Le UM, Qiu F, Shaker DS. Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong antitumor immune responses. Pharm. Res. 24(9), 1645-1652 (2007). (Pubitemid 47206615)
16. McBride S, Hoebe K, Georgel P, Janssen E. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J. Immunol. 177(9), 6122-6128 (2006). (Pubitemid 44628828)
17. Rodriguez BL, Yu Z, Chung W-G, Weiss R, Cui Z. RNA replicase-based plasmid shows antitumor activity. BMC Cancer 11, 110 (2011).
18. Scheiblhofer S, Weiss R, Gabler M, Leitner W W, Thalhamer J. Replicase-based DNA vaccines for allergy treatment. Methods Mol. Med. 127, 221-235 (2006).
19. Leitner W W, Hwang LN, Bergmann-Leitner ES et al. Apoptosis is essential for the increased effcacy of alphaviral replicase-based DNA vaccines. Vaccine 22(11-12), 1537-1544 (2004). (Pubitemid 38446932)
20. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could infuence the response to anti-EGFR drugs. Eur. J. Cancer 39(10), 1348-1354 (2003). (Pubitemid 36773776)
21. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical signifcance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13(1), 3-17 (1992).
22. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol. 11(Suppl. 3), 187-190 (2000).
23. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. 20(9), 2240-2250 (2002). (Pubitemid 34441651)
24. Kullberg EB, Nestor M, Gedda L. Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm. Res. 20(2), 229-236 (2003). (Pubitemid 36269729)
25. Garrido G, Sanchez B, Perez R, Fernandez LE. The antitumor activity of the 7A7 antibody, specifc to murine EGFR, is independent of target expression levels in immunocompetent mice. Biotecnologia Aplicada 24, 26-32 (2007). (Pubitemid 350124226)
26. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 41(3), 429-438 (2000). (Pubitemid 30133961)
27. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Treat. 53(2), 167-176 (1999). (Pubitemid 29161123)
28. 111In]DTPA-hEGF. Nucl. Med. Biol. 34(8), 887-896 (2007). (Pubitemid 350061165)
29. Le UM, Cui Z. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy Int. J. Pharm. 312(1-2), 105-112 (2006).
30. Wang LW, Langley DF. Identifcation and determination of ionic surface active agents. Arch. Environ. Contam. Toxicol. 5(4), 447-456 (1977). (Pubitemid 8156303)
31. Cui Z, Mumper RJ. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation. Bioconjug. Chem. 13(6), 1319-1327 (2002). (Pubitemid 35420026)
32. Carpenter G, Cohen S. Epidermal growth factor. Annu. Rev. Biochem. 48, 193-216 (1979). (Pubitemid 10191090)
33. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6(11), 1867-1875 (1999). (Pubitemid 29531282)
34. Mccray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol. Ther. 14(5), 647-655 (2006). (Pubitemid 44480758)
35. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3(1), e6 (2006).
36. Su AI, Welsh JB, Sapinoso LM et al. Molecular classifcation of human carcinomas by use of gene expression signatures. Cancer Res. 61(20), 7388-7393 (2001). (Pubitemid 32995021)
37. Su AI, Wiltshire T, Batalov S et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101(16), 6062-6067 (2004). (Pubitemid 38520528)
38. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8 (2001). (Pubitemid 32938123)
39. Nakagawa S, Yoshida S, Hirao Y, Kasuga S, Fuwa T. Biological effects of biosynthetic human EGF on the growth of mammalian cells in vitro. Differentiation 29(3), 284-288 (1985). (Pubitemid 16252656)
40. Clayman GL, El-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16(6), 2221-2232 (1998). (Pubitemid 28265061)
41. Hersh EM, Akporiaye E, Harris D et al. Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Hum. Gene Ther. 5(11), 1371-1384 (1994).
42. Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2(9), 985-991 (1996). (Pubitemid 26306836)
43. Hu YH, Tuo X P, Jin ZD, Liu Y, Guo Y, Luo L. Endoscopic ultrasound (EUS)-guided ethanol injection in hepatic metastatic carcinoma: a case report. Endoscopy 42(Suppl. 2), E256-E257 (2010).
44. Lencioni R, Crocetti L, Cioni D et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J. Vasc. Interv. Radiol. 21(10), 1533-1538 (2010).